Navigation Links
RNA Aptamers: A New Paradigm in Cancer Diagnosis and Treatment, New Life Science Webinar Hosted by Xtalks

Toronto, Canada (PRWEB) October 30, 2013

RNA aptamers are an emerging class of molecules demonstrating significant potential in the diagnosis and treatment of human diseases. RNA aptamers are small, single-stranded RNA molecules that are functionally analogous to antibodies. However, RNA aptamers can be produced by chemical synthesis and their small size, low immunogenicity, and other attributes give them important advantages over antibodies. In addition, stable, ribonuclease-resistant RNA aptamers can be readily produced which further extends their use for both in vitro and in vivo applications.

This presentation will focus on the use of RNA aptamers for developing cancer diagnostics and treatments.

Join the panel including speakers from University of Miami, University of Arlington, TX, and University of Iowa, as they discuss techniques and methods involved in:

  •     Selecting and using RNA aptamers as therapeutic agents
  •     Targeted delivery of therapeutics such as siRNA
  •     Development of biosensors/diagnostics for early cancer detection

A Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit: .

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit

Michelle Tran, Marketing Manager
+1 (416) 977-6555 ext 284

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. INCOM Inc. Announces Acquisition of Paradigm Optics
2. Unique properties of graphene lead to a new paradigm for low-power telecommunications
3. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
4. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
5. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
6. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
7. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
8. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
9. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
10. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
11. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
Breaking Biology Technology:
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
Breaking Biology News(10 mins):